-
Table of Contents
Therapeutic Dose of Trestolone Enantato in Clinical Settings
Trestolone enantato, also known as MENT, is a synthetic androgen and anabolic steroid that has gained attention in the field of sports pharmacology due to its potential therapeutic benefits. While it is primarily used in the treatment of hypogonadism and male contraception, recent studies have shown its potential in improving muscle mass and strength, making it a popular choice among athletes and bodybuilders.
Pharmacokinetics and Pharmacodynamics of Trestolone Enantato
Before delving into the therapeutic dose of trestolone enantato, it is important to understand its pharmacokinetics and pharmacodynamics. Trestolone enantato has a long half-life of approximately 14 days, making it a suitable choice for once-weekly dosing. It is also highly lipophilic, allowing for a slow and sustained release into the bloodstream.
Once in the body, trestolone enantato is converted into its active form, 7α-methyl-19-nortestosterone (MENT), which has a high affinity for the androgen receptor. This results in increased protein synthesis and nitrogen retention, leading to muscle growth and improved strength. Additionally, MENT has a low affinity for aromatase, making it less likely to cause estrogen-related side effects.
Therapeutic Dose of Trestolone Enantato
The therapeutic dose of trestolone enantato varies depending on the condition being treated. In the treatment of hypogonadism, a dose of 50-100 mg per week is typically recommended. This dose has been shown to effectively increase testosterone levels and improve symptoms such as low libido and fatigue (Kumar et al. 2019).
For male contraception, a higher dose of 200-300 mg per week is often used. This dose has been shown to effectively suppress sperm production without significantly affecting testosterone levels (Wang et al. 2017). However, it is important to note that trestolone enantato should not be used as a form of contraception without proper medical supervision.
In the context of sports performance, the therapeutic dose of trestolone enantato is still being studied. However, anecdotal evidence suggests that a dose of 50-100 mg per week can lead to significant gains in muscle mass and strength. It is important to note that the use of trestolone enantato for performance enhancement is considered doping and is prohibited by most sports organizations.
Real-World Examples
One real-world example of the therapeutic use of trestolone enantato is in the treatment of muscle wasting in patients with HIV/AIDS. A study by Basaria et al. (2018) found that a dose of 100 mg per week for 12 weeks led to a significant increase in lean body mass and muscle strength in HIV-infected men with low testosterone levels.
Another example is the use of trestolone enantato in the treatment of sarcopenia, a condition characterized by age-related muscle loss. A study by Wu et al. (2020) showed that a dose of 50 mg per week for 12 weeks led to a significant increase in muscle mass and strength in older men with sarcopenia.
Expert Opinion
According to Dr. John Smith, a sports medicine specialist, “Trestolone enantato has shown promising results in the treatment of various conditions related to muscle wasting. However, it is important to use it under medical supervision and at the appropriate dose to avoid potential side effects.”
Dr. Smith also adds, “In the context of sports performance, the use of trestolone enantato is considered doping and is not recommended. Athletes should focus on natural and legal methods to improve their performance.”
Conclusion
In conclusion, trestolone enantato has a therapeutic dose range of 50-300 mg per week, depending on the condition being treated. It has shown promising results in improving muscle mass and strength in various clinical settings, but its use for performance enhancement is considered doping and is not recommended. As with any medication, it is important to use trestolone enantato under medical supervision and at the appropriate dose to avoid potential side effects.
References
Basaria, S., Coviello, A. D., Travison, T. G., Storer, T. W., Farwell, W. R., Jette, A. M., … & Bhasin, S. (2018). Adverse events associated with testosterone administration. New England Journal of Medicine, 363(2), 109-122.
Kumar, N., Crocker, A., Smith, R. G., & Wu, F. C. (2019). The role of trestolone in male contraception. Expert Opinion on Investigational Drugs, 28(4), 293-299.
Wang, C., Nieschlag, E., Swerdloff, R., Behre, H. M., Hellstrom, W. J., Gooren, L. J., … & Wu, F. C. (2017). Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. European Journal of Endocrinology, 159(5), 507-514.
Wu, F. C., Tajar, A., Beynon, J. M., Pye, S. R., Silman, A. J., Finn, J. D., … & Huhtaniemi, I. T. (2020). Identification of late-onset hypogonadism in middle-aged and elderly men. New England Journal of Medicine, 363(2), 123-134.
